Antibiotic-related gut dysbiosis induces lung immunodepression and worsens lung infection in mice.
Antibiotics
Dysbiosis
Fecal microbial transplant
Flt3-ligand
Murine model
Pseudomonas aeruginosa
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
15 10 2020
15 10 2020
Historique:
received:
14
08
2020
accepted:
01
10
2020
entrez:
20
10
2020
pubmed:
21
10
2020
medline:
2
6
2021
Statut:
epublish
Résumé
Gut dysbiosis due to the adverse effects of antibiotics affects outcomes of lung infection. Previous murine models relied on significant depletion of both gut and lung microbiota, rendering the analysis of immune gut-lung cross-talk difficult. Here, we study the effects of antibiotic-induced gut dysbiosis without lung dysbiosis on lung immunity and the consequences on acute P. aeruginosa lung infection. C57BL6 mice received 7 days oral vancomycin-colistin, followed by normal regimen or fecal microbial transplant or Fms-related tyrosine kinase 3 ligand (Flt3-Ligand) over 2 days, and then intra-nasal P. aeruginosa strain PAO1. Gut and lung microbiota were studied by next-generation sequencing, and lung infection outcomes were studied at 24 h. Effects of vancomycin-colistin on underlying immunity and bone marrow progenitors were studied in uninfected mice by flow cytometry in the lung, spleen, and bone marrow. Vancomycin-colistin administration induces widespread cellular immunosuppression in both the lung and spleen, decreases circulating hematopoietic cytokine Flt3-Ligand, and depresses dendritic cell bone marrow progenitors leading to worsening of P. aeruginosa lung infection outcomes (bacterial loads, lung injury, and survival). Reversal of these effects by fecal microbial transplant shows that these alterations are related to gut dysbiosis. Recombinant Flt3-Ligand reverses the effects of antibiotics on subsequent lung infection. These results show that gut dysbiosis strongly impairs monocyte/dendritic progenitors and lung immunity, worsening outcomes of P. aeruginosa lung infection. Treatment with a fecal microbial transplant or immune stimulation by Flt3-Ligand both restore lung cellular responses to and outcomes of P. aeruginosa following antibiotic-induced gut dysbiosis.
Sections du résumé
BACKGROUND
Gut dysbiosis due to the adverse effects of antibiotics affects outcomes of lung infection. Previous murine models relied on significant depletion of both gut and lung microbiota, rendering the analysis of immune gut-lung cross-talk difficult. Here, we study the effects of antibiotic-induced gut dysbiosis without lung dysbiosis on lung immunity and the consequences on acute P. aeruginosa lung infection.
METHODS
C57BL6 mice received 7 days oral vancomycin-colistin, followed by normal regimen or fecal microbial transplant or Fms-related tyrosine kinase 3 ligand (Flt3-Ligand) over 2 days, and then intra-nasal P. aeruginosa strain PAO1. Gut and lung microbiota were studied by next-generation sequencing, and lung infection outcomes were studied at 24 h. Effects of vancomycin-colistin on underlying immunity and bone marrow progenitors were studied in uninfected mice by flow cytometry in the lung, spleen, and bone marrow.
RESULTS
Vancomycin-colistin administration induces widespread cellular immunosuppression in both the lung and spleen, decreases circulating hematopoietic cytokine Flt3-Ligand, and depresses dendritic cell bone marrow progenitors leading to worsening of P. aeruginosa lung infection outcomes (bacterial loads, lung injury, and survival). Reversal of these effects by fecal microbial transplant shows that these alterations are related to gut dysbiosis. Recombinant Flt3-Ligand reverses the effects of antibiotics on subsequent lung infection.
CONCLUSIONS
These results show that gut dysbiosis strongly impairs monocyte/dendritic progenitors and lung immunity, worsening outcomes of P. aeruginosa lung infection. Treatment with a fecal microbial transplant or immune stimulation by Flt3-Ligand both restore lung cellular responses to and outcomes of P. aeruginosa following antibiotic-induced gut dysbiosis.
Identifiants
pubmed: 33076936
doi: 10.1186/s13054-020-03320-8
pii: 10.1186/s13054-020-03320-8
pmc: PMC7574210
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
611Références
Haematologica. 2014 Apr;99(4):638-46
pubmed: 24463214
Nat Rev Immunol. 2017 Apr;17(4):219-232
pubmed: 28260787
J Exp Med. 1996 Nov 1;184(5):1953-62
pubmed: 8920882
Blood. 2017 Feb 9;129(6):729-739
pubmed: 27879260
Lancet Respir Med. 2019 Aug;7(8):710-720
pubmed: 31182406
J Clin Invest. 2018 Aug 1;128(8):3535-3545
pubmed: 29771684
Exp Lung Res. 2009 May;35(4):263-71
pubmed: 19415544
Gut Microbes. 2013 Mar-Apr;4(2):158-64
pubmed: 23333861
Nat Commun. 2017 Nov 15;8(1):1512
pubmed: 29142211
Nat Rev Microbiol. 2011 Apr;9(4):233-43
pubmed: 21358670
N Engl J Med. 2019 Nov 21;381(21):2043-2050
pubmed: 31665575
J Immunol. 2012 Feb 1;188(3):1411-20
pubmed: 22210917
Cell Rep. 2018 Mar 27;22(13):3440-3453.e6
pubmed: 29590614
Physiol Rev. 2010 Jul;90(3):859-904
pubmed: 20664075
PLoS Pathog. 2018 Oct 29;14(10):e1007360
pubmed: 30372491
Mucosal Immunol. 2019 Jul;12(4):843-850
pubmed: 30976087
Gut. 2016 Apr;65(4):575-83
pubmed: 26511795
Int J Mol Sci. 2017 May 24;18(6):
pubmed: 28538663